Maculopathy associated with mefloquine (Lariam) therapy for malaria prophylaxis.
METHODS
We report maculopathy occurring in a patient after 18 months of weekly mefloquine for malaria prophylaxis. Macular retinal pigment epithelium changes bilaterally were visually insignificant, with the patient demonstrating 20/20 corrected visual acuity bilaterally.


CONCLUSIONS
Retinal change as an adverse effect of mefloquine has not previously been reported.
Walker
Randy A
RA
College of Medicine, University of Saskatchewan, and the Department of Ophthalmology, Saskatoon City Hospital, Canada. ra.walker@shaw.ca
Colleaux
Kevin M
KM
D000328:Adult; D000962:Antimalarials / Q000009:adverse effects*; D005451:Fluorescein Angiography; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D008297:Male; D015767:Mefloquine / Q000009:adverse effects*; D010857:Pigment Epithelium of Eye / Q000187:drug effects*; D012164:Retinal Diseases / Q000139:chemically induced*; D014792:Visual Acuity
D000962:Antimalarials; D015767:Mefloquine